Ginkgo Bioworks DNA Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Operating margin | -192%+54.6pp | -246.5%+97.2pp | -343.8%+119pp | -462.4%+120pp | |
| Net margin | -195.4%+45.5pp | -240.9%+114pp | -355.1%+85.6pp | -440.6%+142pp | |
| EBITDA margin | -155.1%+63.7pp | -218.8%+96.9pp | -315.7%+138pp | -453.5%+120pp | |
| Free cash flow margin | -111.7%+56.6pp | -168.3%-34.6pp | -133.7%-70.0pp | -63.7%+35.1pp | |
| Returns | |||||
| Return on equity | -51.1%+9.3pp | -60.3%+2.7pp | -63%+66.8pp | -129.9%+56.2pp | |
| Return on assets | -25%+10.9pp | -36%+6.5pp | -42.5%+48.8pp | -91.3%+42.0pp | |
| Return on invested capital | -46.8%+73.9pp | -120.7%+28.3pp | -149%+335pp | -484.3%+1,406pp | |
| Efficiency | |||||
| Asset turnover | 0.1×0.0× | 0.1×0.0× | 0.1×-0.1× | 0.2×0.0× | |
| Liquidity | |||||
| Current ratio | 4.9×-0.7× | 5.6×-0.5× | 6.1×-2.3× | 8.4×-4.4× | |
| Quick ratio | 4.9×-0.7× | 5.6×-0.5× | 6.1×-2.2× | 8.4×-4.4× | |
| Cash ratio | 2.2×-3.4× | 5.6×-0.4× | 6×-1.9× | 7.9×-3.9× | |
| Leverage | |||||
| Debt-to-equity | 0.9×+0.2× | 0.7×+0.4× | 0.2×0.0× | 0.3×+0.1× | |
| Debt-to-assets | 0.4×+0.1× | 0.3×+0.2× | 0.1×0.0× | 0.2×+0.1× | |
| Per Share | |||||
| Book value per share | $9.17-33.5% | $13.80-38.9% | $22.57-45.4% | $41.34+3,636% | |
| Valuation | |||||
| Market capitalization | $625.16M+24.6% | $564.44M-84.2% | $3.58B+9.2% | $3.28B-76.4% | |
| Enterprise value | $847.19M+45.9% | $426.46M-84.9% | $2.83B+20.4% | $2.35B-81.2% | |
| Price / sales | 4.4×+2.2× | 2.5×-11.8× | 14.2×+7.4× | 6.9×-37.4× | |
| Price / book | 1.4×+0.6× | 0.8×-2.5× | 3.3×+1.4× | 1.9×-7.3× | |
| EV / sales | 6×+3.4× | 1.9×-9.4× | 11.3×+6.3× | 4.9×-34.9× | |
| Free cash flow yield | -26.9%+41.9pp | -67.7%-58.3pp | -9.4%-0.1pp | -9.3%-7.1pp | |
| Earnings yield | -48.7%+45.4pp | -96.9%-72.0pp | -24.9%+39.3pp | -64.2%-51.0pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Ginkgo Bioworks's ratios come from?
- Every ratio is computed from Ginkgo Bioworks's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
